With a new, state-of-the-art bed tower, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis aims to enhance the care and comfort of oncology patients who require hospitalization.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
